Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael B. Atkins, MD
Hoosier Cancer Research Network
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale University, Yale Cancer Center
New Haven, Connecticut, United States
- Georgetown University
Washington D.C., District of Columbia, United States
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
- Northwestern University Feinberg Schooll of Medicine
Chicago, Illinois, United States
- University of Illinois Cancer Center
Chicago, Illinois, United States
- Beth Isreal Deaconess Medical Center
Boston, Massachusetts, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- Columbia University
New York, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Univeristy of Pennsylvania
Philadelphia, Pennsylvania, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Apr 2017
- Primary completion
- 25 Mar 2022
- Completion
- 23 Jan 2025
- Last update posted
- 10 Jul 2025
- Registered enrollment
- 164
- Registry id
- NCT03117309
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.